Do GLP-1s Still Work After 65? What Changes in Older Adults

There's a question that lands in the exam room more often than you'd guess. Sometimes it comes from the person in the chair, 68 and newly curious. Sometimes it comes from the grown kid standing behind them, arms crossed. Either way, it's a version of the same worry: at this age, is a GLP-1 even worth it? Or is that a younger person's drug?

Here's the reassuring part, and it happens to be true: age, on its own, doesn't blunt what these drugs do. The label says as much in plain regulatory language. What genuinely changes after 65 — and more so after 75 — isn't whether the drug works. It's how closely the whole thing needs watching: kidneys, falls, muscle, hydration. Same medicine, tighter monitoring. That's the honest headline. The rest of this is the why.

Age isn't the reason it would stop working

Start there, because it's true and easy to lose under the noise.

Semaglutide — sold as Wegovy for weight and Ozempic for type 2 diabetes — was studied across a wide age range, and the US label puts the finding bluntly.

No overall difference in the effectiveness was observed between patients aged 65 years and older and younger adult patients.

Read that twice if you're the one doing the midnight worrying. It doesn't say "works a little." It says no overall difference. Whatever the drug is doing to appetite and weight in a 45-year-old, it's broadly doing in a 68-year-old too.

And the size of that effect is worth having in front of you. In STEP 1 — the semaglutide trial published in the New England Journal of Medicine in 2021 — the average change in body weight at week 68 was 14.9% on the drug versus 2.4% on placebo. That gap is the reason the whole category exists, and the geriatric line in the label is telling you it holds as the birthdays add up.

One honest caveat, though, because it matters later. Older adults were a minority of who got studied. In the semaglutide obesity program, only about 9% of participants fell in the 65-to-75 band, and roughly 1% were 75 or older. The effect looks steady across ages — but the oldest slice of the evidence is thin, and thin evidence is exactly where you lean harder on caution.

One clarification on the other big name here. Tirzepatide (Zepbound for weight, Mounjaro for diabetes) isn't a pure GLP-1 — it works on two gut hormones, GIP and GLP-1, at once. The age story rhymes across the class, but the specific geriatric language below is drawn from the semaglutide label, which is where it's spelled out.

The scale doesn't tell the whole story after 65

Here's where older bodies genuinely need a different scorecard than younger ones.

For a 40-year-old, a big drop on the scale is close to an unqualified win. For someone at 72, the same drop needs a footnote: what came off? Some of any weight lost is fat, and some is lean tissue — muscle and bone. Younger bodies rebuild lean mass without much thought. Older bodies don't, and they were often starting from less to begin with.

This isn't hand-waving. A 2024 review in Drugs Aging made the point directly: in older adults with obesity, we need trials that track not only weight loss but geriatric endpoints — muscle mass preservation and bone quality — the things that decide whether someone stays steady on their feet at 80.

Losing weight and losing the ability to get out of a chair unassisted are not the same outcome, and for an older adult they can travel together if nobody is watching for it.

So the goal shifts. It's not "biggest number on the scale." It's "fat down, muscle and bone protected." Which quietly turns two dull habits — enough protein, and some resistance work — from optional into the whole point. More on that below.

Past 75, the label gets more careful

Now the part that deserves the most care, told straight and without the horror-movie framing it usually gets online.

In the cardiovascular outcomes trial for semaglutide, patients aged 75 and older reported more hip and pelvis fractures on the drug than on placebo. That's on the US label, and it's the single line the oldest patients — and the families helping them decide — should read most carefully.

A few things keep it in proportion. This is an association reported in one trial's oldest subgroup, not proof the drug snaps bones. And it sits inside a bigger pattern: at 75 and up, serious adverse reactions overall were more common on both the drug and placebo than in younger adults. Very old bodies carry a higher baseline of serious events no matter what's in the syringe — and rapid weight loss, unsteadiness, and thinner muscle plausibly feed the fracture signal as much as the molecule does.

An association in one trial's oldest subgroup is a reason to watch the floor, not a reason to fear the syringe.

None of that makes it a "don't." It makes it a "mind the floor." Falls are the mechanism that turns a hip fracture from a line in a table into a hospital stay. If someone over 75 is on one of these, fall-proofing the house, keeping vision and blood pressure in check, and not dropping weight faster than the body can adjust stop being nice-to-haves. The stand-up dizziness that can ride along with these drugs is its own small hazard here; we get into it in why GLP-1s can make you lightheaded, and it's worth a read if balance is already a question.

Kidneys don't love being run dry

The other risk that hits older bodies harder runs through the kidneys, and the chain is simpler than it sounds.

The most common side effects of this class are gastrointestinal — nausea, vomiting, diarrhea. The US label carries postmarketing reports of acute kidney injury, in some cases serious, mostly in people whose GI reactions led to dehydration. In plain terms: it's usually not the drug reaching in and harming the kidney directly. It's the dehydration from being sick that drops your fluid volume, and low volume is what strains the kidney.

Why does age tilt this the wrong way? Two reasons that stack. Kidney function naturally declines with the decades, so there's less reserve to spare. And thirst — the built-in alarm that tells you to drink — gets quieter with age, so an older person can be genuinely dried out without feeling parched. A younger body feels the warning and reaches for water. An older one may not.

So the everyday move is unglamorous, and it works: keep fluids and electrolytes going in through the day, and treat a run of vomiting or diarrhea as a reason to call, not to tough out. The electrolyte side of this — why plain water alone sometimes isn't enough — is its own topic, and we go deep on it in hydration and electrolytes on a GLP-1. If kidney health is already on your chart, the fuller picture lives in GLP-1s and kidney function.

Muscle is the quiet thing to protect

If there's one habit that earns its keep on a GLP-1 after 65, it's protecting muscle while the fat comes off.

The logic connects straight back to the Drugs Aging point. Fast weight loss with no reason to hold onto muscle tends to shed some lean mass along with the fat, and in an older body that's the difference between "lighter and stronger" and "lighter and frailer." Frailer means slower on the stairs, shakier on a curb, quicker to fall — which loops right back to the fracture worry above.

Two levers do most of the work, and neither is exotic. Eat enough protein, spread across the day rather than dumped into one meal — harder than it sounds once a GLP-1 has quietly turned the appetite down. And keep some resistance in your week: bands, light weights, sit-to-stands off a kitchen chair, whatever your knees and shoulders allow. The signal "I'm still using these muscles" is what tells the body to keep them.

This is a big enough subject that it has its own home. How much lean mass is actually at stake, and what preserves it, is laid out in muscle loss on GLP-1s — for an older reader, I'd treat that one as required reading, not a footnote.

Three tiers of caution, worst first

Age-specific stuff aside, the general safety map for these drugs is worth seeing whole, so the serious and the routine don't blur into one anxious smear. Three tiers, heaviest first.

At the top sits a hard line that has nothing to do with age. In the US, the semaglutide label carries a boxed warning tied to thyroid C-cell tumor risk, and it names a flat contraindication: a personal or family history of medullary thyroid carcinoma (MTC), or the inherited condition Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This isn't a weigh-the-tradeoffs item. If that history runs in the family, the drug is off the table.

One grade down is a warning, not a ban: acute pancreatitis. The label doesn't forbid treatment over it upfront — it tells clinicians to stop the drug if pancreatitis is suspected. The practical read is that severe, persistent stomach pain isn't something to breathe through. It's a reason to get checked, soon.

Then the everyday tier, where most of what you'll actually feel lives: the gastrointestinal reactions — nausea, vomiting, diarrhea, constipation. Loudest early, or just after a dose steps up, and usually the manageable background hum of being on one of these rather than a red flag. For an older adult, the reason this tier matters more isn't that it's worse — it's that it's the on-ramp to the dehydration-and-kidney chain above.

One boundary on all of it. "Boxed warning" and "contraindication" are US FDA terms describing the US label. If you're reading from the UK, the EU, Australia, or elsewhere, your own regulator's wording, approved uses, and even which brand sits on the pharmacy shelf can differ. The tiers of seriousness travel well; the exact language is worth checking against your own country's label.

Low and slow beats fast and sorry

Put it together and a strategy falls out, and it lines up almost boringly well with good geriatric prescribing in general: start low, go slow, watch closely.

Slower dose escalation gives an older gut more time to adapt, which keeps the nausea-and-dehydration domino from ever tipping. A gentler pace of weight loss gives muscle and bone a fair chance to keep up. Regular check-ins — kidney function, how the appetite and eating are really going, whether balance has shifted — turn "set it and forget it" into something safer. And the number on the scale stops being the only scoreboard; steady on the feet and strong out of a chair count for at least as much.

The one thing that isn't on the menu is freelancing the dose. Whether it holds, rises, or pauses is a call for whoever prescribes it, with your history and your other medicines in view — not a knob to turn at the kitchen table because a week felt off. If staying at a lower dose for the long haul is the plan, the maintenance evidence is worth knowing, and we walk through it in keeping the weight off past the two-year mark.

What to bring to your next appointment

If you keep one idea from all this, keep the frame: after 65, a GLP-1 isn't a drug you're too old for — it's a drug you use with the volume turned up on monitoring.

The effectiveness question has a calm answer. The label shows no overall difference in how well it works past 65, and the STEP 1 numbers — 14.9% versus 2.4% at week 68 — are what that's holding onto. Past 75 the evidence thins and the caution thickens: more fractures and more serious events reported in that oldest group, which is a reason for closer watching, not automatic avoidance. The specifically-older risks worth naming out loud to your clinician are the kidneys and dehydration, the muscle and bone you don't want to lose, and the falls you want to design around.

Everything here comes from the drug's approved US label and the published trials behind it — not from your chart, which is the one document that decides your plan. Bring the questions that fit your life: your kidney numbers, your fall history, what you're doing for protein and strength, every other medicine in the drawer. Turn the vague worry into a specific conversation, and the answer you walk out with tends to be a lot steadier than the one you'd have found at midnight.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app